NPS Pharmaceuticals, Inc. (NPSP) Initiates Global Registration Study Of Teduglutide In Pediatric Patients With Short Bowel Syndrome
1/2/2014 9:24:21 AM
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
Help employers find you! Check out all the jobs and post your resume.
comments powered by